BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Distillery Therapeutics

Cancer

Michael Leviten
March 20, 2018 11:11 PM UTC

Cell culture and mouse studies suggest inhibition of SRF or its co-activator MLK1 could help treat drug-resistant BCC. In one human and two mouse SMO inhibitor-resistant BCC cell lines, a tool compoun...

BCIQ Company Profiles

Stanford University

BCIQ Target Profiles

Megakaryoblastic leukemia translocation 1 (MLK1)

Serum response factor (c-fos serum response element-binding transcription factor) (SRF)

Smoothened (SMO)

BCIQ Company Profiles

Stanford University

BCIQ Target Profiles

Megakaryoblastic leukemia translocation 1 (MLK1)

Serum response factor (c-fos serum response element-binding transcription factor) (SRF)

Smoothened (SMO)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2025 BioCentury Inc. All Rights Reserved.
Copyright © 2025 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS